Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Tanespimycin (17-AAG) Chemical Structure

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. Tanespimycin (17-AAG) purchased from Selleck.

    (A) Treatment of DIPG cells with an HSP90 inhibitor, 17-AAG, resulted in decreased invasion toward SVZ hNPC CM at high doses. (B) Cell viability of DIPG cells treated with increasing doses of 17-AAG, by the CellTiter-Glo assay.

    Cell, 2017, 170(5):845-859.e19. Tanespimycin (17-AAG) purchased from Selleck.

  • Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. Tanespimycin (17-AAG) purchased from Selleck.

    Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. Tanespimycin (17-AAG) purchased from Selleck.

  • Co-IP analyses of direct interaction between HSP90 and HIF-1α in 17-AAG (5 μM)-treated HSCs using antibodies against HSP90, HIF-1α or IgG (n = 2).

    Br J Pharmacol, 2017, 174(5):409-423. Tanespimycin (17-AAG) purchased from Selleck.

    UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. Tanespimycin (17-AAG) purchased from Selleck.

  • Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. Tanespimycin (17-AAG) purchased from Selleck.

    SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. Tanespimycin (17-AAG) purchased from Selleck.

  • Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. Tanespimycin (17-AAG) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NXzOdHI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LIXWlEPTB;MD6wNFA{ODNizszN MkTZV2FPT0WU
IST-MEL1 M1XFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMECwOFA4KM7:TR?= MnznV2FPT0WU
NCI-SNU-1 MmrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe4T3pKSzVyPUCuNFAzODdizszN NHLqcmJUSU6JRWK=
FADU M2Pzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMECyNFkh|ryP MVjTRW5ITVJ?
C32 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HHT2lEPTB;MD6wNFMxPCEQvF2= NXfEWY5mW0GQR1XS
D-566MG MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\TdWlEPTB;MD6wNFM6KM7:TR?= Mof4V2FPT0WU
LXF-289 MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;WcWlEPTB;MD6wNFQyQSEQvF2= NXPGeJhEW0GQR1XS
HGC-27 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLuTWM2OD1yLkCwOVEh|ryP Mn7BV2FPT0WU
RPMI-7951 NHryRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDvVYNxUUN3ME2wMlAxPzF5IN88US=> MX;TRW5ITVJ?
HSC-3 NX:3SnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf4TWM2OD1yLkCwPVI6KM7:TR?= MWnTRW5ITVJ?
MIA-PaCa-2 NILweY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMEGwNFkh|ryP NGWyVldUSU6JRWK=
KS-1 NGTGWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMEGzOVUh|ryP NULiOXh[W0GQR1XS
CAL-51 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonMTWM2OD1yLkCxOFA2KM7:TR?= NH7WN|hUSU6JRWK=
MDA-MB-361 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjKUIhuUUN3ME2wMlAyPDl3IN88US=> NGDoU4xUSU6JRWK=
TI-73 M{HjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;5TWM2OD1yLkCxO|k3KM7:TR?= NIfRSnZUSU6JRWK=
AGS NF3KUZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHYTmdKSzVyPUCuNFE6OzhizszN MWDTRW5ITVJ?
NCI-H460 NFzNOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHhVHZKSzVyPUCuNFE6PzRizszN MmfNV2FPT0WU
A204 M4rnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnlO|lPUUN3ME2wMlAzOjR7IN88US=> MYXTRW5ITVJ?
CHL-1 NFG2WGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwMEKyOVEh|ryP MULTRW5ITVJ?
DU-4475 M3[5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG1NpJ3UUN3ME2wMlAzOjZzIN88US=> MkH5V2FPT0WU
CGTH-W-1 M1rBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[3TWM2OD1yLkCyN|Q6KM7:TR?= M{[zbXNCVkeHUh?=
HCC2218 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r1O2lEPTB;MD6wNlQ6PCEQvF2= NFzWZmZUSU6JRWK=
A2780 NUX0TYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvpXINsUUN3ME2wMlAzPTNzIN88US=> MX\TRW5ITVJ?
NCI-H720 NX\RcGF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu5VVRUUUN3ME2wMlAzPTR4IN88US=> NFv0W5FUSU6JRWK=
NCI-N87 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEK1PVMh|ryP NGnMNoNUSU6JRWK=
CHP-212 NVnsSFZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonSTWM2OD1yLkCyOlI5KM7:TR?= NWXyPXozW0GQR1XS
NCI-H23 NWXLVpdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LMfGlEPTB;MD6wNlY3PSEQvF2= M1nme3NCVkeHUh?=
D-263MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC5clZKSzVyPUCuNFI4QDZizszN NX:yPGdUW0GQR1XS
ME-180 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMEK4PVEh|ryP MofEV2FPT0WU
SW982 Mm\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEK5PVkh|ryP NFi3ZXVUSU6JRWK=
OE19 NV\GR4doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PCb2lEPTB;MD6wN|A4PyEQvF2= MoLoV2FPT0WU
SK-LU-1 NEe5UlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DsfGlEPTB;MD6wN|A5OiEQvF2= M1\wUnNCVkeHUh?=
H4 NXzafFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjQWJRtUUN3ME2wMlA{ODlizszN MmLoV2FPT0WU
HT-144 MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfxPJk3UUN3ME2wMlA{ODl|IN88US=> MYnTRW5ITVJ?
SK-UT-1 Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEOxO|gh|ryP MnrHV2FPT0WU
D-336MG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjUdZRKSzVyPUCuNFM{ODlizszN NGS1VJRUSU6JRWK=
MDA-MB-175-VII NEC0VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPjNmJzUUN3ME2wMlA{OzV2IN88US=> NXK4b4M1W0GQR1XS
GAMG MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDwTWM2OD1yLkCzOFM2KM7:TR?= MmqyV2FPT0WU
CP50-MEL-B NFHoRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P6WWlEPTB;MD6wN|Q2KM7:TR?= MWnTRW5ITVJ?
OVCAR-5 NF7WU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEO0PEDPxE1? Mn\nV2FPT0WU
SK-MES-1 NWXJWXM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMEO2NFYh|ryP M1judnNCVkeHUh?=
VM-CUB-1 NUXS[mR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjEdmJKSzVyPUCuNFM3PTdizszN NHS0VI9USU6JRWK=
WM-115 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILucI9KSzVyPUCuNFM4PjJizszN NYrDNWlrW0GQR1XS
DSH1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCxd3NuUUN3ME2wMlA{QDB5IN88US=> M2G4VHNCVkeHUh?=
Becker MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMEO4PFUh|ryP MlPDV2FPT0WU
SW962 M4LmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G5dGlEPTB;MD6wN|k1PSEQvF2= MnrpV2FPT0WU
TYK-nu M4K2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEO5PFUh|ryP MnHaV2FPT0WU
HO-1-N-1 M4nYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW3cItKSzVyPUCuNFQxOjFizszN MUHTRW5ITVJ?
T98G Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS0TWM2OD1yLkC0NVA{KM7:TR?= MVzTRW5ITVJ?
ACN NVvvdmdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnncXFKSzVyPUCuNFQyPjJizszN NV7Y[WViW0GQR1XS
SW780 NWHDelVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPhS|dKSzVyPUCuNFQzODNizszN MmfhV2FPT0WU
Detroit562 NWq1[Zo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPL[XZKSzVyPUCuNFQzOzlizszN NGnIc3hUSU6JRWK=
BB49-HNC M1u5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTzTWM2OD1yLkC0NlQ{KM7:TR?= NX3STWRuW0GQR1XS
HN NFL6SJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMESyO|Ih|ryP NXrOXZdIW0GQR1XS
H9 M1q4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzkU4h[UUN3ME2wMlA1OzdzIN88US=> MVjTRW5ITVJ?
VA-ES-BJ MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe0SINyUUN3ME2wMlA1PDR5IN88US=> NI[2OHhUSU6JRWK=
MEL-JUSO NV\EN4ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwMES0O|Uh|ryP NH[0NGdUSU6JRWK=
BT-474 NHnvT2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMES1JO69VQ>? M2HROXNCVkeHUh?=
CaR-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL5PWJHUUN3ME2wMlA1PTR7IN88US=> NX\NSlVvW0GQR1XS
PSN1 Mle5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF74fJRKSzVyPUCuNFQ3ODNizszN NVvCZYZ4W0GQR1XS
KYSE-510 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;hfpVKSzVyPUCuNFQ3PDlizszN NIm0SWpUSU6JRWK=
KP-4 NHX5VGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrQTWM2OD1yLkC0O|U{KM7:TR?= NYfRbXhxW0GQR1XS
KYSE-410 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHixUINKSzVyPUCuNFQ4PzJizszN NHrGTndUSU6JRWK=
G-402 NETVU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMES3PFkh|ryP NXX5TGJMW0GQR1XS
DOK MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPsRphKSzVyPUCuNFQ6ODJizszN Mn\vV2FPT0WU
COR-L88 NXTKOVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwMES5NVIh|ryP NWjmUVRPW0GQR1XS
SKG-IIIa MljIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvxTlF7UUN3ME2wMlA1QTh4IN88US=> MorPV2FPT0WU
AN3-CA MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMEWg{txO M2PKeXNCVkeHUh?=
SW48 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn2XXBKSzVyPUCuNFUxOzlizszN MWrTRW5ITVJ?
YKG-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OxUmlEPTB;MD6wOVA4OSEQvF2= NEXRTnRUSU6JRWK=
KYSE-150 NYnybYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnNSHU3UUN3ME2wMlA2OjN3IN88US=> NE\me4pUSU6JRWK=
HuO-3N1 M1mzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorUTWM2OD1yLkC1NlM4KM7:TR?= MmLiV2FPT0WU
LB1047-RCC NETX[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PXTGlEPTB;MD6wOVI6PiEQvF2= Mn[0V2FPT0WU
NCI-H2030 NH3NNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS3W2lKSzVyPUCuNFU1OTRizszN MmeyV2FPT0WU
YH-13 NIfwfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP2eZhKSzVyPUCuNFU4OjJizszN MVnTRW5ITVJ?
5637 NUfneodFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rMdmlEPTB;MD6wOVc1KM7:TR?= NF;jT3hUSU6JRWK=
LOXIMVI M3fNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LHbmlEPTB;MD6wOVg4OiEQvF2= MXHTRW5ITVJ?
GT3TKB MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPYNI5KSzVyPUCuNFU6PDJizszN NU\rT4V3W0GQR1XS
TCCSUP Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TKTmlEPTB;MD6wOVk3PCEQvF2= MX7TRW5ITVJ?
EPLC-272H NYDhOXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwME[yNFUh|ryP MUTTRW5ITVJ?
LU-99A Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrsTWM2OD1yLkC2NlM4KM7:TR?= NYXZbI1QW0GQR1XS
NCI-H1755 NX3VVZM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XNeWlEPTB;MD6wOlM1OSEQvF2= M4mwTnNCVkeHUh?=
KM12 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwME[zOFgh|ryP NYTnVZN4W0GQR1XS
SF295 M3LFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvETWM2OD1yLkC2OFUzKM7:TR?= NEDQPZNUSU6JRWK=
MZ2-MEL NHq4[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwME[1OVMh|ryP M{LVR3NCVkeHUh?=
HEC-1 Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwME[1PFgh|ryP MUPTRW5ITVJ?
SW684 NFPJTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoewTWM2OD1yLkC2OVkyKM7:TR?= MWrTRW5ITVJ?
SF539 M{XkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\GSJNIUUN3ME2wMlA3PjhzIN88US=> NVHjNI1wW0GQR1XS
GMS-10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwME[2PVkh|ryP NGqzSG1USU6JRWK=
MV-4-11 NIHhc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwME[4NFMh|ryP NXHCe4pTW0GQR1XS
HT-29 NUe2NWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTqeINPUUN3ME2wMlA3QTF7IN88US=> M{PEfHNCVkeHUh?=
23132-87 M4DLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qTWM2OD1yLkC2PVUh|ryP M1vWcHNCVkeHUh?=
SW620 NUn1U5Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfhWotKSzVyPUCuNFcxOjZizszN NYS2SFJrW0GQR1XS
HCC1806 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33r[mlEPTB;MD6wO|E{OSEQvF2= MXTTRW5ITVJ?
Hs-578-T M2L5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEeyNFgh|ryP MnfEV2FPT0WU
A2058 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrQbXdKSzVyPUCuNFczOjhizszN MXLTRW5ITVJ?
MEL-HO M3XZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnUfGxwUUN3ME2wMlA4OjV3IN88US=> NF70XIVUSU6JRWK=
HCC2998 NFy5O5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz3OYpPUUN3ME2wMlA4OzR5IN88US=> M3LYOXNCVkeHUh?=
HuO9 NFzoOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLsTWM2OD1yLkC3OVg6KM7:TR?= M4C3WHNCVkeHUh?=
CAL-39 NF\udY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXNPIhKSzVyPUCuNFc4PjZizszN MoTwV2FPT0WU
M14 NGfueoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnQTWM2OD1yLkC3PVE{KM7:TR?= MYrTRW5ITVJ?
BFTC-909 NY\VeWZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H3eWlEPTB;MD6wO|k3QSEQvF2= NXLlSVZIW0GQR1XS
TE-11 NEfiUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvhTWM2OD1yLkC3PVk3KM7:TR?= NELSeVlUSU6JRWK=
TGBC1TKB M1fheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDLSWhvUUN3ME2wMlA5ODR|IN88US=> MVPTRW5ITVJ?
L-363 M360PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmntTWM2OD1yLkC4NlA3KM7:TR?= M1X5enNCVkeHUh?=
A431 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTZVnVPUUN3ME2wMlA5OjFizszN M4[1eXNCVkeHUh?=
MKN45 M{K0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;IfWlEPTB;MD6wPFIyQSEQvF2= NVTQOJVzW0GQR1XS
HT-1080 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHpUVc4UUN3ME2wMlA5PDN7IN88US=> NVzUV21qW0GQR1XS
OVCAR-8 NV\0No5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMEi2NlIh|ryP MkPQV2FPT0WU
LCLC-97TM1 Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXXSlZNUUN3ME2wMlA5PzJ6IN88US=> NUHLPHF4W0GQR1XS
M059J NXPHbFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXWyNWZsUUN3ME2wMlA6ODJ5IN88US=> M1jxRnNCVkeHUh?=
SK-MEL-2 MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7jSItKSzVyPUCuNFkxPiEQvF2= M4nMRXNCVkeHUh?=
TE-1 M4n5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEmyNFQh|ryP MlfUV2FPT0WU
KYSE-180 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jQXWlEPTB;MD6wPVI3OiEQvF2= NX;mZm9rW0GQR1XS
D-247MG MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjzVnlKSzVyPUCuNFk1PTVizszN NVHNclFoW0GQR1XS
8-MG-BA M33SUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTyPGFKSzVyPUCuNFk1PzJizszN M2myV3NCVkeHUh?=
NCI-H1792 NHuzTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTLTWM2OD1yLkC5OlE5KM7:TR?= MVPTRW5ITVJ?
MCF7 Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;COYJKSzVyPUCuNFk3PzdizszN M{[0cHNCVkeHUh?=
NCI-H2122 Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEm3OFUh|ryP MWrTRW5ITVJ?
EFO-27 MofCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHFTWM2OD1yLkC5PVk4KM7:TR?= MoD6V2FPT0WU
LB2241-RCC Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnsbmU2UUN3ME2wMlExODV2IN88US=> MoniV2FPT0WU
SN12C NYD4dmZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPEWndKSzVyPUCuNVAyODdizszN MknTV2FPT0WU
A498 NXjJR5JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLkTWM2OD1yLkGwNVgh|ryP MVXTRW5ITVJ?
PANC-03-27 NVj3SI9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH22bnBKSzVyPUCuNVAzQDZizszN NFjZVW5USU6JRWK=
NCI-H1581 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jxWWlEPTB;MD6xNFI6KM7:TR?= NH;DZXJUSU6JRWK=
U-87-MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfFclhtUUN3ME2wMlExOzB5IN88US=> MXnTRW5ITVJ?
G-401 M2fIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTQTWM2OD1yLkGwN|U{KM7:TR?= M2rNTnNCVkeHUh?=
SiHa M3zBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnFXHBKSzVyPUCuNVA1QDZizszN M3fiW3NCVkeHUh?=
U251 NX7OTGN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;XT2FKSzVyPUCuNVA2OjVizszN MV;TRW5ITVJ?
MMAC-SF Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXftSJZOUUN3ME2wMlExPTNzIN88US=> NUPvdmpRW0GQR1XS
BB65-RCC MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTuTWM2OD1yLkGwOVU1KM7:TR?= NV;vcpB2W0GQR1XS
NKM-1 NFXRUWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXqN2ViUUN3ME2wMlExPjZ4IN88US=> NVXNdnhUW0GQR1XS
HD-MY-Z M{X4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXVRo5rUUN3ME2wMlExQDd|IN88US=> M3vtZnNCVkeHUh?=
TGBC11TKB NYjXSoNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMUC5NFMh|ryP M3jK[nNCVkeHUh?=
COLO-679 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\wSG0xUUN3ME2wMlEyOjFzIN88US=> NF:wbXlUSU6JRWK=
TE-8 M3fIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMUGyOlQh|ryP NGjEUZNUSU6JRWK=
SK-MEL-28 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrDb2E3UUN3ME2wMlEyOzJzIN88US=> MUXTRW5ITVJ?
SH-4 M4S5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\jU2hiUUN3ME2wMlEyOzV4IN88US=> MV7TRW5ITVJ?
KALS-1 M4XEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMUGzPVMh|ryP NVu4SmxOW0GQR1XS
RKO NVuxfJdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMUG3OlQh|ryP MWPTRW5ITVJ?
OMC-1 M2DkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr2XHFIUUN3ME2wMlEyPzl5IN88US=> NUDUc2xQW0GQR1XS
BT-549 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTPNXhKSzVyPUCuNVE4QTlizszN NWnJbWx7W0GQR1XS
NCI-H28 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i5UGlEPTB;MD6xNVgyPyEQvF2= MY\TRW5ITVJ?
RXF393 NWPrcpdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n5[WlEPTB;MD6xNVk5OiEQvF2= MoHZV2FPT0WU
COLO-829 NYDWT|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjOTWM2OD1yLkGyNFA2KM7:TR?= MWnTRW5ITVJ?
HMV-II M{DGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXnTWM2OD1yLkGyNFIh|ryP NGC1bYFUSU6JRWK=
SW1990 M33EPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\Bd3lkUUN3ME2wMlEzOTV5IN88US=> NHewfGNUSU6JRWK=
NCI-H1437 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHESFZKSzVyPUCuNVIyPTdizszN MWTTRW5ITVJ?
SNB75 NVjiS3N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPZTWM2OD1yLkGyNVY6KM7:TR?= NGPqOWtUSU6JRWK=
EW-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PMOmlEPTB;MD6xNlY3OSEQvF2= MVvTRW5ITVJ?
SAS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMUK2PUDPxE1? Mn60V2FPT0WU
NCI-H1666 NViwdlRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\UTmlEPTB;MD6xNlc4PCEQvF2= MkWxV2FPT0WU
A375 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDZcGdKSzVyPUCuNVI4PzhizszN NXzUXJpKW0GQR1XS
CAMA-1 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX0[HNKSzVyPUCuNVI6OjRizszN NWTncpBFW0GQR1XS
HuP-T4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMUK5OFMh|ryP Mn\GV2FPT0WU
NCI-H292 NFHpcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDUNFA6UUN3ME2wMlE{OTFizszN NXPtOJJWW0GQR1XS
PC-14 NHO2XVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTmTWM2OD1yLkGzNlEyKM7:TR?= MV\TRW5ITVJ?
BPH-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm4eFlKSzVyPUCuNVM1OSEQvF2= MlHtV2FPT0WU
GAK NFPZcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nSXGlEPTB;MD6xN|U3PyEQvF2= M2rSVXNCVkeHUh?=
VMRC-RCZ NFzSXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\kcnlKSzVyPUCuNVM4PjJizszN MUDTRW5ITVJ?
SK-MEL-24 NELGPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjtNJFzUUN3ME2wMlE{QDdizszN NHnmT|JUSU6JRWK=
LB831-BLC M{DZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPkTWM2OD1yLkGzPFg{KM7:TR?= MVfTRW5ITVJ?
NCI-H2452 M2HDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TtNWlEPTB;MD6xN|k2PiEQvF2= MnO2V2FPT0WU
RT-112 MlTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzOUIxKSzVyPUCuNVQxOzVizszN MYLTRW5ITVJ?
GP5d Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7NTWM2OD1yLkG0NVA1KM7:TR?= M3jR[XNCVkeHUh?=
LC-2-ad NIDDdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL0XJU{UUN3ME2wMlE1OTJzIN88US=> MkfoV2FPT0WU
MPP-89 NXjOR4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fkb2lEPTB;MD6xOFEzPSEQvF2= M3nLR3NCVkeHUh?=
NUGC-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7sTWM2OD1yLkG0OFc5KM7:TR?= MX;TRW5ITVJ?
GI-1 M1vkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2noXmlEPTB;MD6xOFU2QCEQvF2= MkTaV2FPT0WU
HCC1419 NVu3[WszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknjTWM2OD1yLkG0OVc3KM7:TR?= M2XLfXNCVkeHUh?=
SW1573 M2ntdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;xU2lEPTB;MD6xOFc2QCEQvF2= NFO5do1USU6JRWK=
NCI-H2347 MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13ae2lEPTB;MD6xOFg{QSEQvF2= NVPZWoxlW0GQR1XS
Mewo MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXYTWM2OD1yLkG0PFg6KM7:TR?= NFzGVolUSU6JRWK=
639-V NGDXeGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO5dZhKSzVyPUCuNVUxOTNizszN NYrpS3VQW0GQR1XS
AsPC-1 NUfLbW5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jISWlEPTB;MD6xOVIzPSEQvF2= NF;R[lFUSU6JRWK=
NCI-H1648 NF7CfHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[5OmlEPTB;MD6xOVI{OiEQvF2= MXPTRW5ITVJ?
786-0 NF\hV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPXRo9KSzVyPUCuNVU{QDFizszN NUT6d|Z4W0GQR1XS
ETK-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDDTWM2OD1yLkG1PUDPxE1? MoW5V2FPT0WU
BxPC-3 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2npO2lEPTB;MD6xOVk3PiEQvF2= NH;Tb2RUSU6JRWK=
CAL-62 NWfINVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLNPYxKSzVyPUCuNVYyPjlizszN NVezbZRUW0GQR1XS
HCC1937 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvGSo1YUUN3ME2wMlE3Ojd3IN88US=> M4nxO3NCVkeHUh?=
NCI-H1299 NFvTcGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nGc2lEPTB;MD6xOlI5PSEQvF2= MkDHV2FPT0WU
SW1088 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPqTWM2OD1yLkG2OFE{KM7:TR?= Mk\DV2FPT0WU
FTC-133 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvKR5hKSzVyPUCuNVY2PCEQvF2= MkfEV2FPT0WU
OC-314 M336T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnCfI9GUUN3ME2wMlE3PjlizszN M4XJfnNCVkeHUh?=
SCC-9 NF3JO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHSZ2NKSzVyPUCuNVY4OTZizszN MV3TRW5ITVJ?
HT-1376 M1\UNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTvNpRKSzVyPUCuNVY6OzZizszN NVPFUWIzW0GQR1XS
U-2-OS NFnwT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\vemlEPTB;MD6xO|E4OyEQvF2= NEDFe4lUSU6JRWK=
COLO-824 NEjHbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nDXGlEPTB;MD6xO|I6PCEQvF2= NY\LZ3FrW0GQR1XS
BB30-HNC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;jNHdKSzVyPUCuNVc{OyEQvF2= MWXTRW5ITVJ?
NCI-H2087 NEDDSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjRTWM2OD1yLkG3N|Y5KM7:TR?= NHHtdmhUSU6JRWK=
NCI-H2170 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfMO5FnUUN3ME2wMlE4PTN4IN88US=> NHnSZXRUSU6JRWK=
SK-OV-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\DbINRUUN3ME2wMlE4PTdzIN88US=> NWjt[5V6W0GQR1XS
MZ7-mel NWfvR3RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rXdWlEPTB;MD6xO|Y1QSEQvF2= Mlv0V2FPT0WU
NCI-H650 M1HZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHDSWdXUUN3ME2wMlE4Pjh{IN88US=> M1LWcHNCVkeHUh?=
KOSC-2 MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjrU5hKUUN3ME2wMlE4PzN2IN88US=> NUHSendEW0GQR1XS
SCC-4 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn20TWM2OD1yLkG3O|c4KM7:TR?= M1fjcHNCVkeHUh?=
MDA-MB-157 NFm1blBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrtb5hyUUN3ME2wMlE5ODh{IN88US=> NYjITW1sW0GQR1XS
KYSE-520 NEP0RpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFS2WGlKSzVyPUCuNVgzKM7:TR?= Mmm4V2FPT0WU
LK-2 M4nq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;6dJg6UUN3ME2wMlE5OzB|IN88US=> NYrMVGFKW0GQR1XS
KNS-81-FD M3WwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT5TWlkUUN3ME2wMlE5Ozl2IN88US=> NXLCZ4hlW0GQR1XS
IGROV-1 M1K2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorrTWM2OD1yLkG4OFQ{KM7:TR?= MVPTRW5ITVJ?
DEL NGq4WIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;Wd2lEPTB;MD6xPFQ2KM7:TR?= MlP3V2FPT0WU
NCI-H1395 Mmn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHETWM2OD1yLkG4OlgzKM7:TR?= NXjpdphPW0GQR1XS
JEG-3 NUfwXmE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r6fGlEPTB;MD6xPFcxPSEQvF2= NUizT3lFW0GQR1XS
BCPAP NIP5WmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjEcppKSzVyPUCuNVg5PzJizszN NFG5SVRUSU6JRWK=
CAL-27 NWPTSWd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXocHNKSzVyPUCuNVkxOjJizszN MYrTRW5ITVJ?
RD M4\4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\CSnBOUUN3ME2wMlE6OTF|IN88US=> NYXYRZk{W0GQR1XS
RVH-421 NIDMb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:wTldKSzVyPUCuNVkyOTZizszN M{Lzb3NCVkeHUh?=
Capan-2 NIWzeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\IZ|lKSzVyPUCuNVkzPTZizszN NXXqZm1tW0GQR1XS
COLO-680N MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmm5TWM2OD1yLkG5N|Y1KM7:TR?= M{i5[nNCVkeHUh?=
NCI-H1650 NXG4cGw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC3bZBvUUN3ME2wMlIxODV5IN88US=> NVm4ZXMzW0GQR1XS
SBC-5 MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMkCxNVgh|ryP MX;TRW5ITVJ?
U031 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMkC1OFch|ryP Ml;tV2FPT0WU
S-117 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoP3TWM2OD1yLkKwOVY1KM7:TR?= M1m2RXNCVkeHUh?=
DoTc2-4510 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzKbmNYUUN3ME2wMlIxPzZ7IN88US=> Ml24V2FPT0WU
AM-38 M4TDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO4TWM2OD1yLkKwPFQ5KM7:TR?= M2O3WHNCVkeHUh?=
A172 NWH1d3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMkGwNlIh|ryP NFP3PFFUSU6JRWK=
HPAF-II MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljLTWM2OD1yLkKxNlY1KM7:TR?= M3jON3NCVkeHUh?=
769-P MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT3SmhRUUN3ME2wMlIyOjhizszN NH;Xb4NUSU6JRWK=
MFE-280 NX3lUJpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HhR2lEPTB;MD6yNVI6QCEQvF2= NFuwNXNUSU6JRWK=
TE-9 NV;j[4tzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMkG3PFYh|ryP NYPBTI5ZW0GQR1XS
C2BBe1 NUPpcVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzHTWM2OD1yLkKyNVkh|ryP NEf6NYZUSU6JRWK=
EoL-1-cell Mn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL5TFdPUUN3ME2wMlIzOjB|IN88US=> MlzyV2FPT0WU
G-361 NW[xZWg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L5WmlEPTB;MD6yNlY5OiEQvF2= NYnUemw4W0GQR1XS
KYSE-270 MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL1TWM2OD1yLkKzNFg1KM7:TR?= Mm\yV2FPT0WU
TK10 NVezR2NPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMkOxNVch|ryP NGLWOW1USU6JRWK=
ML-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzpTWM2OD1yLkKzNVE6KM7:TR?= MXrTRW5ITVJ?
MHH-ES-1 Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\GO4hKSzVyPUCuNlM3QDFizszN MlzrV2FPT0WU
BHY M2TMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMkO2PVEh|ryP M3PJSXNCVkeHUh?=
LS-513 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHizZZlKSzVyPUCuNlM6PjFizszN Mn7xV2FPT0WU
COLO-678 MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL2ZmdKSzVyPUCuNlQxPDRizszN MWHTRW5ITVJ?
NCI-H747 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jCOGlEPTB;MD6yOFE3QSEQvF2= NYLTUI1vW0GQR1XS
K5 M4L2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LYfGlEPTB;MD6yOFM5KM7:TR?= MkLmV2FPT0WU
OS-RC-2 MlvHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj3PVhMUUN3ME2wMlI1PTB7IN88US=> NYDpdog4W0GQR1XS
KINGS-1 MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofZTWM2OD1yLkK0OVI6KM7:TR?= Mnq3V2FPT0WU
SCC-25 NIPUNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;oeG5mUUN3ME2wMlI1PTZ|IN88US=> MUDTRW5ITVJ?
CAPAN-1 M3\sdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe5TWM2OD1yLkK0O|g{KM7:TR?= MYPTRW5ITVJ?
ESS-1 M1izVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nabWlEPTB;MD6yOFgxPSEQvF2= M3T6VnNCVkeHUh?=
TE-6 NGK1WXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMkW3OUDPxE1? M{jNRnNCVkeHUh?=
LB2518-MEL NG\1enZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPhTlJjUUN3ME2wMlI2Pzd5IN88US=> M3SwbHNCVkeHUh?=
COLO-800 NWHhZYpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMkW4NVIh|ryP M1nhNXNCVkeHUh?=
LU-134-A MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMk[xN|Yh|ryP NXK2eGczW0GQR1XS
NCI-H1155 NXHtWlJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPaVpFKSzVyPUCuNlYyPjJizszN MVHTRW5ITVJ?
MFM-223 NIHVZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEmwOWRKSzVyPUCuNlY{PjNizszN NVjFTGZ7W0GQR1XS
HTC-C3 NYW5bWlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvNTWM2OD1yLkK2OVA3KM7:TR?= MluwV2FPT0WU
HCT-116 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Tkd2lEPTB;MD6yOlU6QSEQvF2= MWXTRW5ITVJ?
Ca-Ski MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTHTWM2OD1yLkK2Olc5KM7:TR?= NX;rW2xOW0GQR1XS
SBC-1 NWHI[45bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\uXpo{UUN3ME2wMlI3PzR{IN88US=> Ml7zV2FPT0WU
NB69 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMkewPFch|ryP NVvNXI1[W0GQR1XS
J82 M2TrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TZW2lEPTB;MD6yO|I3PSEQvF2= MUTTRW5ITVJ?
U-118-MG NVzvNpBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjGTWM2OD1yLkK3OVc6KM7:TR?= NGX5O3BUSU6JRWK=
NCI-H1355 NXHKVnFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fZXGlEPTB;MD6yPFA4PCEQvF2= M3nCNnNCVkeHUh?=
NCI-H1048 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMki5OVYh|ryP NVXEWFBrW0GQR1XS
SW954 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnLUYJMUUN3ME2wMlI6OjJ5IN88US=> MXjTRW5ITVJ?
NMC-G1 NWCwb4s6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nxSWlEPTB;MD6yPVI4PyEQvF2= M2nQZXNCVkeHUh?=
SW1710 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMkm0PVQh|ryP MlPnV2FPT0WU
KY821 MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULndlBXUUN3ME2wMlI6QDd{IN88US=> MkjYV2FPT0WU
HCC38 NFnNcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXr4cG43UUN3ME2wMlMxODd6IN88US=> NGHhZ4lUSU6JRWK=
NCI-SNU-5 M4nYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvBZ|FKSzVyPUCuN|A2PCEQvF2= NH\QRlNUSU6JRWK=
ES8 NXX4OHRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HYdWlEPTB;MD6zNFc5PCEQvF2= MofHV2FPT0WU
COLO-792 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwM{GyOVEh|ryP MWjTRW5ITVJ?
BFTC-905 NVuzXlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrRV3I2UUN3ME2wMlMyPTJzIN88US=> M1zhdXNCVkeHUh?=
ChaGo-K-1 NHf4eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHOwZpZKSzVyPUCuN|E4OTVizszN MXrTRW5ITVJ?
Daoy NFnLNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHKxU3VKSzVyPUCuN|E4OjNizszN M4fXR3NCVkeHUh?=
SJSA-1 NXnV[pJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;XT2lEPTB;MD6zNVg1PyEQvF2= NWW1OFFNW0GQR1XS
KNS-62 NEna[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HuUmlEPTB;MD6zNlA5QCEQvF2= Mo\XV2FPT0WU
CAKI-1 NWPhenRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljpTWM2OD1yLkOyNVEyKM7:TR?= Mlq1V2FPT0WU
UACC-62 NYHkco5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zrS2lEPTB;MD6zNlIzPyEQvF2= NEHQV21USU6JRWK=
HuCCT1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS0OZdpUUN3ME2wMlMzOjh|IN88US=> Mmm3V2FPT0WU
CTB-1 M4\p[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjTT45KSzVyPUCuN|I4PTNizszN MUDTRW5ITVJ?
NTERA-S-cl-D1 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nk[GlEPTB;MD6zNlg{PiEQvF2= Mn75V2FPT0WU
T-24 NYj5fIl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwM{OxOVkh|ryP MoTqV2FPT0WU
KYSE-70 NVe5b|gzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LxSGlEPTB;MD6zN|I5OyEQvF2= MW\TRW5ITVJ?
SW626 NEfwcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDHOm9xUUN3ME2wMlM{PTN{IN88US=> NXrGUotrW0GQR1XS
LB996-RCC MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvuWFVMUUN3ME2wMlM{PjF7IN88US=> NGnQVWpUSU6JRWK=
DMS-273 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwM{O5NVYh|ryP MWfTRW5ITVJ?
SW1783 NGnySpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jZcWlEPTB;MD6zN|k6PyEQvF2= M4[3fHNCVkeHUh?=
KU812 NFHzOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkO5TWM2OD1yLkO0NFM5KM7:TR?= NIi0PXpUSU6JRWK=
HSC-2 NF\GelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjk[VNrUUN3ME2wMlM1ODV|IN88US=> MVfTRW5ITVJ?
A3-KAW M17UO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3sNGxKSzVyPUCuN|QyPjJizszN NF3p[oVUSU6JRWK=
COLO-684 NVywWGxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vtcWlEPTB;MD6zOFUxOSEQvF2= NWD3U2F3W0GQR1XS
NCI-H2405 M165VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KwTmlEPTB;MD6zOFY{OSEQvF2= NHL5S2VUSU6JRWK=
NCI-H2228 NF61e5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTxTWM2OD1yLkO1N|U4KM7:TR?= NXnmUWUzW0GQR1XS
NB13 M3XpPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iyN2lEPTB;MD6zOlgzQSEQvF2= M1zuTXNCVkeHUh?=
no-11 NYfGOVBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzjfZhHUUN3ME2wMlM3QTVizszN MkXEV2FPT0WU
DK-MG M2nabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwM{exPFgh|ryP MonyV2FPT0WU
NBsusSR NYjk[VVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwM{eyPFUh|ryP NYnGRZdqW0GQR1XS
KP-N-YS M3r6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwM{e0OlMh|ryP M3jFe3NCVkeHUh?=
CFPAC-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnxXZZKSzVyPUCuN|c2OThizszN M2nWV3NCVkeHUh?=
KARPAS-45 NXzaU4FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uxbGlEPTB;MD6zO|g3OiEQvF2= MWLTRW5ITVJ?
NCI-H1793 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXqWWt1UUN3ME2wMlM5PTFizszN M4TqN3NCVkeHUh?=
HCE-T MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Lwe2lEPTB;MD6zPFYxOyEQvF2= NUf3[YRjW0GQR1XS
NCI-H520 NXm2S4pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3JO|VsUUN3ME2wMlM5PzB|IN88US=> Ml34V2FPT0WU
HCC2157 Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzYTWM2OD1yLkO4O|gyKM7:TR?= MWfTRW5ITVJ?
EW-18 M1:z[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn2TWM2OD1yLkO4PVQyKM7:TR?= NV;qbplpW0GQR1XS
RO82-W-1 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorPTWM2OD1yLkO5Olk6KM7:TR?= NXnTVHdIW0GQR1XS
HuP-T3 M3fHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L5[WlEPTB;MD60NFE1OyEQvF2= NX\JToh3W0GQR1XS
PANC-10-05 NUXtOZRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorFTWM2OD1yLkSxNVch|ryP NUK5OVFiW0GQR1XS
NCI-H1703 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\xXmJZUUN3ME2wMlQyPDR4IN88US=> NYrld5FIW0GQR1XS
TE-10 NFjRXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHaXoFKSzVyPUCuOFE1PDdizszN NGLNZmNUSU6JRWK=
HOS M{Xo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwNEG2PFIh|ryP MWrTRW5ITVJ?
LN-405 Mn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT0TWM2OD1yLkSxOlg4KM7:TR?= NEfpeXNUSU6JRWK=
A427 M3TGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLhTWM2OD1yLkSxPVgyKM7:TR?= NXTWZ|lNW0GQR1XS
CAL-12T Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nSWGlEPTB;MD60Nlc5KM7:TR?= M2nOSXNCVkeHUh?=
SW756 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwNESxPFMh|ryP NFfacYVUSU6JRWK=
YAPC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG2TWM2OD1yLkS1NFgh|ryP MWrTRW5ITVJ?
GOTO NVPESnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwNEWxOkDPxE1? MlqyV2FPT0WU
C3A MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe0NVRKSzVyPUCuOFU1OzdizszN Ml[4V2FPT0WU
UM-UC-3 NHPOTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPETWM2OD1yLkS1OFch|ryP NGLJVGVUSU6JRWK=
NCI-H1573 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P4TmlEPTB;MD60OVU3QSEQvF2= NHv1NXRUSU6JRWK=
LS-411N M2exSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HlWWlEPTB;MD60OlUzPyEQvF2= NYPWTZlOW0GQR1XS
COR-L23 NXG2TJQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTzO2lKSzVyPUCuOFY4PjRizszN NFvDZ4ZUSU6JRWK=
HCE-4 NF;tbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnFN|BKSzVyPUCuOFc1PDZizszN NUXHZ2Y1W0GQR1XS
NCI-H2291 NYj6fWdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfCTWM2OD1yLkS3PFk3KM7:TR?= MnvIV2FPT0WU
A101D M2fFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnMTWM2OD1yLkS4NFU{KM7:TR?= M3O1XnNCVkeHUh?=
HT-3 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL4ZXJ4UUN3ME2wMlQ5OjF5IN88US=> MUnTRW5ITVJ?
HOP-62 NV76bnFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwNEm4OlUh|ryP NGHhT|dUSU6JRWK=
PC-3 NVTEVnNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwNUG1NFch|ryP Ml\4V2FPT0WU
CTV-1 M2[2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PoXGlEPTB;MD61NlY3QSEQvF2= NXz5d29mW0GQR1XS
PANC-08-13 NV\TSpp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjrO2lKSzVyPUCuOVMyPzdizszN MWrTRW5ITVJ?
CAL-120 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXW4O5l5UUN3ME2wMlU{Ozl7IN88US=> Mo\NV2FPT0WU
UMC-11 M2\lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXsXXBzUUN3ME2wMlU2OjN2IN88US=> M4jjV3NCVkeHUh?=
MSTO-211H M1nNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwNUW3OlIh|ryP NXK5RW9OW0GQR1XS
NCI-H2126 MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfGNoFKSzVyPUCuOVY5OTVizszN NX;ofZdIW0GQR1XS
SNU-C2B MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;NTWM2OD1yLkW3PVc4KM7:TR?= MkTaV2FPT0WU
DBTRG-05MG NV7ZNVhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPq[nhMUUN3ME2wMlU5ODV|IN88US=> NUnXOll2W0GQR1XS
MKN1 M1m5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDZTWM2OD1yLkW4O|g{KM7:TR?= MWnTRW5ITVJ?
ES3 M{G3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwNUmxNlQh|ryP NV;YSoR7W0GQR1XS
OVCAR-3 NV;lXIFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXK[ldKSzVyPUCuOVk{PDFizszN Mk\HV2FPT0WU
ACHN MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HIWGlEPTB;MD62NFU3QSEQvF2= NGDrZnBUSU6JRWK=
SW872 M2PhdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwNkC3OlMh|ryP M1rVOHNCVkeHUh?=
CP66-MEL NETzTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwNkC5Olkh|ryP NF:5dWhUSU6JRWK=
NCI-H661 NELFNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XES2lEPTB;MD62NVExPCEQvF2= M4\NR3NCVkeHUh?=
UACC-893 NEHB[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DD[2lEPTB;MD62N|Y5OSEQvF2= Mln5V2FPT0WU
JVM-3 NEDT[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCzTWM2OD1yLk[zPFA1KM7:TR?= NWfVdZRTW0GQR1XS
SF268 NIXFdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwNkSzOFkh|ryP NYCySWxDW0GQR1XS
OCI-AML2 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwNkWzPVch|ryP MkWzV2FPT0WU
RPMI-8226 NYrI[nl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNk[zNlMh|ryP M{e0SnNCVkeHUh?=
MKN28 MnyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPPTZhpUUN3ME2wMlY3PjJ2IN88US=> NVL5Ong6W0GQR1XS
MDA-MB-453 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPrTWM2OD1yLk[3NVgh|ryP MlvSV2FPT0WU
BV-173 NHTxZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwNki2O|kh|ryP MnvaV2FPT0WU
NCI-H358 NELpW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXkTWM2OD1yLk[4O|I3KM7:TR?= NF7YZlhUSU6JRWK=
NCI-H1651 MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XrSGlEPTB;MD63JO69VQ>? MVLTRW5ITVJ?
MDA-MB-415 M4m0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwN{C4Nlkh|ryP MWTTRW5ITVJ?
8305C M4H2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLMTWM2OD1yLkeyOFk5KM7:TR?= MlXRV2FPT0WU
EFM-19 NXzR[pJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXpTWM2OD1yLkezOlcyKM7:TR?= NUH2WVNXW0GQR1XS
RERF-LC-MS M2XtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHOPJdKSzVyPUCuO|Q3OTNizszN MnfBV2FPT0WU
A388 NWLrSWJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TGTWlEPTB;MD63OlQ3PyEQvF2= MXLTRW5ITVJ?
GI-ME-N NUXWPWRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ST|RKSzVyPUCuO|czOzVizszN NEKxOGVUSU6JRWK=
IGR-1 NGPoflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwN{mwOFMh|ryP NIDuT5ZUSU6JRWK=
LNCaP-Clone-FGC M2jCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{i4dWlEPTB;MD64NFAxPCEQvF2= M{DveXNCVkeHUh?=
SK-MEL-3 M3\4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD6b3Q6UUN3ME2wMlgyPTB6IN88US=> NWDORYluW0GQR1XS
UACC-257 NHr3emFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwOEKyN|Eh|ryP M4DM[3NCVkeHUh?=
OE33 M4SyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SxS2lEPTB;MD64OVExOSEQvF2= NUOwOYNbW0GQR1XS
QIMR-WIL MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfjTnpKSzVyPUCuPFUyPDFizszN MWPTRW5ITVJ?
NCI-H2009 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwOEWzNVEh|ryP M4THWHNCVkeHUh?=
NCI-H522 MliyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnrXHJ3UUN3ME2wMlg4Pzh|IN88US=> M1j1eHNCVkeHUh?=
Saos-2 NFfDOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TU[2lEPTB;MD64O|g4OSEQvF2= MVLTRW5ITVJ?
NB17 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwOEiwNlUh|ryP NXu3R3c{W0GQR1XS
D-392MG NVXHV2RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIewNZRKSzVyPUCuPFk{PTZizszN NFW3RldUSU6JRWK=
SHP-77 M2fmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFz2XXhKSzVyPUCuPVA1QDVizszN NXHUWHhuW0GQR1XS
SK-MEL-30 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTSV|hKSzVyPUCuPVEyQDVizszN Mm\2V2FPT0WU
GCIY NHzHXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLpTWM2OD1yLkmxPFQ{KM7:TR?= NIDMbGRUSU6JRWK=
HCC70 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHiTWM2OD1yLkmyNFU6KM7:TR?= NE[1UpBUSU6JRWK=
LU-65 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XRR2lEPTB;MD65NlU6OSEQvF2= MlzxV2FPT0WU
NCI-H1563 M1vqWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HWeWlEPTB;MD65OFg3PSEQvF2= M{jkfXNCVkeHUh?=
KURAMOCHI NX;wd3NZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zYUGlEPTB;MD65OVE6OiEQvF2= MkKxV2FPT0WU
PA-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\l[|ZQUUN3ME2wMlk2PDJ2IN88US=> MmrWV2FPT0WU
NOS-1 MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zIV2lEPTB;MD65O|Q5QSEQvF2= M4\nVHNCVkeHUh?=
NCI-H69 M2nDb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITZRohKSzVyPUCuPVc3OzRizszN MnzZV2FPT0WU
KYSE-450 NGfybHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwOUi2NlYh|ryP MWnTRW5ITVJ?
8505C M1;ifWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwOUm5PFIh|ryP M3fCO3NCVkeHUh?=
TGBC24TKB NV7CXYx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfXTWM2OD1zLkCwNFg1KM7:TR?= MoPoV2FPT0WU
PFSK-1 NIDtTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVroSI9UUUN3ME2xMlAyPDJ6IN88US=> M3fwSnNCVkeHUh?=
EKVX NHj3endIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwMEOxNlEh|ryP MoS2V2FPT0WU
RCM-1 M3e1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnYd2FKSzVyPUGuNFU2ODdizszN NUXjbYZwW0GQR1XS
SW900 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTFwMEe4N{DPxE1? MYnTRW5ITVJ?
D-542MG M{\vUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTFwMEe4OVUh|ryP MVLTRW5ITVJ?
SK-PN-DW NVTuc3g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfURpVmUUN3ME2xMlExODV4IN88US=> NF3UUIRUSU6JRWK=
NCI-H727 NFPVXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[3TWM2OD1zLkGwNVU1KM7:TR?= M4izdXNCVkeHUh?=
SW837 NIDaTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL3TWM2OD1zLkGwPVU1KM7:TR?= NHy4TmFUSU6JRWK=
BT-20 NITjXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTJdmdjUUN3ME2xMlEyOjB2IN88US=> MmG2V2FPT0WU
RH-18 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwMUOxNFMh|ryP Mn\GV2FPT0WU
TE-12 M3nZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXqTnBiUUN3ME2xMlE{OzN|IN88US=> NYjueIxDW0GQR1XS
NB10 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\mfGhKSzVyPUGuNVM{PDRizszN NXi1Z5ZzW0GQR1XS
AU565 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwMUW5O|Mh|ryP MX7TRW5ITVJ?
OAW-42 NF;PSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle2TWM2OD1zLkG4N|A3KM7:TR?= M3\kVnNCVkeHUh?=
DJM-1 M3K5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPB[YtwUUN3ME2xMlE6QDhzIN88US=> MULTRW5ITVJ?
HH MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHrb4pKUUN3ME2xMlI{QDNzIN88US=> MoL1V2FPT0WU
LAMA-84 NXXCS5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDTTWM2OD1zLkK3N|k1KM7:TR?= NFraVGpUSU6JRWK=
KNS-42 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDDSmFRUUN3ME2xMlMxOjl4IN88US=> M4PDOHNCVkeHUh?=
NCI-H2052 NX2zRYxCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzzTWM2OD1zLkOwOVA4KM7:TR?= M2rhcnNCVkeHUh?=
MLMA M17Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTFwM{K0NFch|ryP MXfTRW5ITVJ?
NB12 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mny3TWM2OD1zLkO1OlM3KM7:TR?= MV;TRW5ITVJ?
NCI-H1838 MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jsWWlEPTB;MT6zOlMxPiEQvF2= NEXqdI1USU6JRWK=
NCI-H526 M1zSNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnTWGVKSzVyPUGuN|c5PTNizszN MYLTRW5ITVJ?
LS-123 NFPsfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFwM{mwPVQh|ryP M3K2T3NCVkeHUh?=
HDLM-2 NEfy[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX6SlBKSzVyPUGuN|kzPzFizszN M4f0ZXNCVkeHUh?=
MC-IXC NFu2eYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\sV5M5UUN3ME2xMlQzOzdzIN88US=> M1uwWnNCVkeHUh?=
HCT-15 MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzXTWM2OD1zLkSzNFY5KM7:TR?= MmLOV2FPT0WU
NCI-H596 MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofpTWM2OD1zLkS1NFYyKM7:TR?= M2jnSHNCVkeHUh?=
ZR-75-30 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLjTWM2OD1zLkS3NFgzKM7:TR?= NHvvbIJUSU6JRWK=
A704 NF;SSGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTH[olKSzVyPUGuOlY2PjNizszN MVHTRW5ITVJ?
OVCAR-4 NEPnXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm3TWM2OD1zLk[5OlA4KM7:TR?= MXHTRW5ITVJ?
SW1417 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\PTWM2OD1zLkeyPFQ6KM7:TR?= MWXTRW5ITVJ?
CAS-1 MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTFwN{O5N|Yh|ryP MofTV2FPT0WU
IST-SL1 M2j1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLYTWM2OD1zLke5O|U6KM7:TR?= NY\rTGNwW0GQR1XS
A253 NFnncIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjmR49KSzVyPUGuPFIzOzlizszN NXzlOJUzW0GQR1XS
EW-16 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33jcWlEPTB;MT64Nlg4PSEQvF2= NHz4cWJUSU6JRWK=
SK-NEP-1 NEnxSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTJO|dFUUN3ME2xMlg3QTh6IN88US=> NHO1VYRUSU6JRWK=
NCI-H226 MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHETWM2OD1zLki5N|U6KM7:TR?= MY\TRW5ITVJ?
HOP-92 NVyyc5FMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3FTWM2OD1zLkm2NFk6KM7:TR?= MX3TRW5ITVJ?
NCI-H441 M2SxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJwMEKzN|ch|ryP MkjoV2FPT0WU
LU-139 NEnMPZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJwMEOxNVQh|ryP NIrLbYZUSU6JRWK=
SJRH30 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6zfY1YUUN3ME2yMlA1OjV|IN88US=> NXzod442W0GQR1XS
MG-63 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvLbY5vUUN3ME2yMlE1OTFzIN88US=> NWm3NYZ{W0GQR1XS
NH-12 NIfOfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJwMUWwNFYh|ryP MULTRW5ITVJ?
NB7 NGnXUYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[5fpZKSzVyPUKuNVk3PzNizszN NGXBRm1USU6JRWK=
LB771-HNC M2n5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHxTWM2OD1{LkKwOVk2KM7:TR?= NEjFN4dUSU6JRWK=
HCC1569 MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJwMkS1PFMh|ryP NXfaOYtuW0GQR1XS
D-283MED NUD1eoNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJwMkS3PFIh|ryP NXPQXVNCW0GQR1XS
J-RT3-T3-5 NE\mbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:3TWM2OD1{LkK1N|UyKM7:TR?= MkDPV2FPT0WU
ATN-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vsbmlEPTB;Mj6zN|A5OiEQvF2= NUXq[YNvW0GQR1XS
HCC1954 MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XwU2lEPTB;Mj6zOFQxQCEQvF2= M4\4bnNCVkeHUh?=
SCC-15 M2TOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJwM{mzNVIh|ryP NWS0cFA4W0GQR1XS
COLO-668 M2DPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXXdWZSUUN3ME2yMlQ{OiEQvF2= MkLrV2FPT0WU
LB373-MEL-D MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDiOHNKSzVyPUKuOVQ3PzdizszN NXzhS3l6W0GQR1XS
no-10 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJwNUS5OFch|ryP M{nXeHNCVkeHUh?=
HT-1197 M3rs[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG4OG5KSzVyPUKuOlMyQDhizszN MUHTRW5ITVJ?
DU-145 M1\OXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn76TWM2OD1{Lke5NVYzKM7:TR?= NYXMS4tlW0GQR1XS
SK-N-AS NEnqVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWH1U|VnUUN3ME2yMlg1Pjl{IN88US=> MmHlV2FPT0WU
MOLT-4 MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS1ZldKSzVyPUKuPFU{OjJizszN NEjyeG1USU6JRWK=
EW-22 M{fGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jPfmlEPTB;Mj65Nlg1OSEQvF2= MmjsV2FPT0WU
DB NFzTRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\qTWM2OD1{Lkm3O|U6KM7:TR?= NF\mfldUSU6JRWK=
HL-60 NWTUTHZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL6VmxKSzVyPUOuNFQ{PzZizszN NWDvcpRzW0GQR1XS
SK-N-DZ MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLaTWM2OD1|LkC1NFc2KM7:TR?= NHTpPHJUSU6JRWK=
NY NGPZZ4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;heWlEPTB;Mz6wPFU1OiEQvF2= MnruV2FPT0WU
T47D MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXHTmZKSzVyPUOuNVA2PThizszN MVfTRW5ITVJ?
NCI-H2029 Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7jTWM2OD1|LkKyOFc4KM7:TR?= MXvTRW5ITVJ?
KARPAS-299 Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DQS2lEPTB;Mz6yOlAzPyEQvF2= NVrudpdjW0GQR1XS
KM-H2 MkfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTNwM{C2PEDPxE1? MoHtV2FPT0WU
CHP-134 MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LiPGlEPTB;Mz60O|M6KM7:TR?= M2T5TXNCVkeHUh?=
22RV1 NX33fo0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37kUGlEPTB;Mz60PVE3QCEQvF2= M4LXfXNCVkeHUh?=
NB5 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTNwNUC2PFkh|ryP M3vONnNCVkeHUh?=
CW-2 NYnmPW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTxfIJbUUN3ME2zMlU2OzF2IN88US=> MYLTRW5ITVJ?
EFO-21 M1KxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6zTWM2OD1|LkW2PVQh|ryP NHPLVW5USU6JRWK=
HuH-7 MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWr1UIpnUUN3ME2zMlU5PDF2IN88US=> MmD4V2FPT0WU
ALL-PO MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTNwNkKzN|Uh|ryP NYC4PYZVW0GQR1XS
EM-2 MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Me4NKSzVyPUOuOlkxOTFizszN MVrTRW5ITVJ?
KLE NYizRnRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILPRYRKSzVyPUOuO|MxOjlizszN NYTOXoxyW0GQR1XS
NEC8 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXGS2hRUUN3ME2zMlkyQDB6IN88US=> NVL3eYtbW0GQR1XS
KP-N-YN NVyzcYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTNwOUO0O|Yh|ryP MVvTRW5ITVJ?
SK-MEL-1 MmDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjWTpd2UUN3ME20MlA{PTF6IN88US=> M1LIZ3NCVkeHUh?=
CAL-54 NVWySXpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfOVJJ7UUN3ME20MlA2QTFizszN MXPTRW5ITVJ?
MS-1 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRwMU[xOVUh|ryP MV\TRW5ITVJ?
NCI-H209 M3KwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3QNVVKSzVyPUSuNlk6QTlizszN NGjoU4RUSU6JRWK=
NOMO-1 NGTjd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnJZVBKSzVyPUSuN|IyOzFizszN NFvtUoxUSU6JRWK=
RPMI-2650 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;GTWM2OD12LkO2N|I4KM7:TR?= M{izU3NCVkeHUh?=
NCI-H810 NULISGZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrLco5JUUN3ME20MlM6PzN4IN88US=> NE\QN|VUSU6JRWK=
Ca9-22 NWjVPJIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIWyZ29KSzVyPUSuOFU3QTFizszN NGXHW5FUSU6JRWK=
ES4 MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXuTWM2OD12LkS3NFk2KM7:TR?= Mo\oV2FPT0WU
ES6 M3fRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRwNEm2OVch|ryP MYDTRW5ITVJ?
DMS-114 M4n0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW0cVlKSzVyPUSuOVQ3QTFizszN NXH2Wm9CW0GQR1XS
ONS-76 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\3VIpKSzVyPUSuOVc6PSEQvF2= NEi5cHlUSU6JRWK=
K-562 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmq4TWM2OD12LkezPFE1KM7:TR?= NUPmR5ZFW0GQR1XS
MHH-NB-11 M4H0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;qRmZKSzVyPUSuO|U1PjFizszN M4L0cHNCVkeHUh?=
Calu-3 MmHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTRwN{i1OFgh|ryP NVTjTng5W0GQR1XS
HT55 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLZTWM2OD12Lki0OVQ2KM7:TR?= NGLUO3pUSU6JRWK=
SK-N-FI MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTRwOEWwNFkh|ryP NUnX[FQxW0GQR1XS
ES1 M3fwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TQTmlEPTB;ND64OlA2PyEQvF2= NVnzfJpqW0GQR1XS
SF126 NVX0SWZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTRwOUOxPFQh|ryP NXfyclNyW0GQR1XS
ES5 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHYZpRKSzVyPUWuNVI1OjdizszN MV3TRW5ITVJ?
LoVo NX:0dlcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTVwMUW4O|Eh|ryP M2fEd3NCVkeHUh?=
SNU-387 NXewSng1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17ScGlEPTB;NT6zNlM{QSEQvF2= MlSzV2FPT0WU
C8166 NFTlNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7WTWM2OD13LkO2N|M6KM7:TR?= NXfDV4NMW0GQR1XS
LS-1034 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nOfGlEPTB;NT60NlMxPyEQvF2= NY\BVpppW0GQR1XS
GR-ST MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfMOGZzUUN3ME21MlUzOjBzIN88US=> MUnTRW5ITVJ?
NCI-H1092 M{jNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7kVnhQUUN3ME21MlczQDR|IN88US=> MWHTRW5ITVJ?
647-V MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTkO4tKSzVyPUWuO|Q4ODZizszN NW[3VZVRW0GQR1XS
EW-13 MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTVwN{[2Nlch|ryP MWXTRW5ITVJ?
KGN M4rvWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXsbHRKSzVyPU[uNFk6OjFizszN MX3TRW5ITVJ?
D-423MG MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[3TWM2OD14LkSwNlg1KM7:TR?= MlPVV2FPT0WU
ECC10 NVPzS2FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofkTWM2OD15LkGwNVAyKM7:TR?= NUK5bHRLW0GQR1XS
TE-5 NIfDZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTdwNEGyPVgh|ryP NI[0d5dUSU6JRWK=
P12-ICHIKAWA M4LuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfLTWM2OD15LkS1OVI{KM7:TR?= M1XiZXNCVkeHUh?=
NCI-H82 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTdwNEW3NFEh|ryP MkXQV2FPT0WU
NCI-H1993 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z6cmlEPTB;Nz64N|A3OyEQvF2= MWrTRW5ITVJ?
RH-1 NWj2eXd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVX4TZViUUN3ME23Mlg2OjR2IN88US=> NWnJeGRMW0GQR1XS
SW948 NX[yZ2RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPRTVVKSzVyPUeuPVYxPDlizszN MnzlV2FPT0WU
CAL-33 NX7xUZNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHaN5FKSzVyPUeuPVk6OzhizszN NHfDd2tUSU6JRWK=
U-266 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP4TWM2OD16LkG1O|c4KM7:TR?= NGGzSIpUSU6JRWK=
CAL-72 MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWT5[WlwUUN3ME24MlIxOzJizszN NGT6[3FUSU6JRWK=
SNU-423 NUnyNJZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T1WGlEPTB;OT6zOlY3PiEQvF2= Mm\lV2FPT0WU
KG-1 MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXoVlRKSzVyPUmuOVg1PTZizszN MmrBV2FPT0WU
HCC1395 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PYR2lEPTB;OT65NlM2OiEQvF2= NI\FZnpUSU6JRWK=
BE-13 M3n6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\IWG5KSzVyPUGwMlg5QTJizszN NXf4fnlRW0GQR1XS
MKN7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkSzTWM2OD1zMD65O|Y2KM7:TR?= M4LTd3NCVkeHUh?=
697 NWfjc3d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\2UmNKSzVyPUGxMlE1PzJizszN MUTTRW5ITVJ?
LU-135 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXUfWVHUUN3ME2xNU4zOzB5IN88US=> MVrTRW5ITVJ?
ES7 Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;xeGlEPTB;MUGuN|MyOyEQvF2= MXjTRW5ITVJ?
SK-HEP-1 NGPEeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFzLke2OFYh|ryP NX3VeZlSW0GQR1XS
BEN MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjVe5dKSzVyPUGxMlg2OSEQvF2= Mn3kV2FPT0WU
NCI-H1770 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHScpVYUUN3ME2xNk4yOjZizszN M4HKV3NCVkeHUh?=
SW13 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF{LkG1OFEh|ryP NWnVXHlOW0GQR1XS
MZ1-PC MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M325O2lEPTB;MUKuOVQ2OiEQvF2= MnvzV2FPT0WU
Mo-T NYTGbodLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH75WpVKSzVyPUGyMlc1OjFizszN MoryV2FPT0WU
HLE NIiwU3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF{LkiyNVUh|ryP NXf4VmxZW0GQR1XS
RCC10RGB Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu3TWM2OD1zMz62O|Eh|ryP NGG5XnZUSU6JRWK=
COLO-320-HSR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnFc3N6UUN3ME2xN{44OzhzIN88US=> NEPL[Y9USU6JRWK=
BHT-101 M13N[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHaTWM2OD1zMz64N|Q2KM7:TR?= NF7hS|dUSU6JRWK=
OCUB-M MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjtTWM2OD1zND6xOlAzKM7:TR?= NHjyVIdUSU6JRWK=
MEG-01 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF2LkO3NFgh|ryP M4DLVXNCVkeHUh?=
RS4-11 NVvlWXFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHoTWM2OD1zND63OFIh|ryP M1fMN3NCVkeHUh?=
MN-60 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITGO4tKSzVyPUG0Mlc5QTRizszN NXjETZBFW0GQR1XS
NCI-H1304 M{XzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjzUYhKSzVyPUG1MlA1OjVizszN MlywV2FPT0WU
Ramos-2G6-4C10 NXrJSYVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PnVmlEPTB;MUWuNFU5OSEQvF2= MX\TRW5ITVJ?
NCI-H2342 NE\1c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLpTWM2OD1zNT6yNFQ1KM7:TR?= MXzTRW5ITVJ?
LAN-6 NIfa[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF3LkS0NVQh|ryP MlrCV2FPT0WU
JVM-2 NFnycZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:5TWM2OD1zNT61O|Q5KM7:TR?= MonaV2FPT0WU
P30-OHK MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHMTWM2OD1zNj6wOlE1KM7:TR?= NELSUYxUSU6JRWK=
C-33-A MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;KU2lEPTB;MU[uOlIyPCEQvF2= NEHu[ndUSU6JRWK=
RPMI-8866 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXBTWM2OD1zNj64OFk3KM7:TR?= NYr4NWM4W0GQR1XS
NCI-H630 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[xNGlEPTB;MU[uPFU{PyEQvF2= MnzEV2FPT0WU
KYSE-140 NGnQ[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfyOFlKSzVyPUG3MlIxOjhizszN M1HkO3NCVkeHUh?=
T84 NXnjUHppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHSfZJJUUN3ME2xPE45Pjl3IN88US=> MYjTRW5ITVJ?
KU-19-19 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4X2dmlEPTB;MUiuPVYxQCEQvF2= NFTGZ|BUSU6JRWK=
BALL-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF7LkOzPVkh|ryP MWrTRW5ITVJ?
Calu-6 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS5TWM2OD1zOT60PVIh|ryP NWXkXVdHW0GQR1XS
EGI-1 NV7hb2JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUezfHFbUUN3ME2xPU42QThizszN NILNToVUSU6JRWK=
MFH-ino M3;Bcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnT6TWM2OD1zOT63OFU1KM7:TR?= MYHTRW5ITVJ?
GB-1 NHfpXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH63fZhKSzVyPUKwMlM2OzVizszN MYDTRW5ITVJ?
NCI-H1693 NHnVZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHaWWFKSzVyPUKwMlY2ODVizszN NWS0XWhiW0GQR1XS
SW1116 M1nZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7UfIRKSzVyPUKwMlk{PjJizszN M3n1dHNCVkeHUh?=
H-EMC-SS MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXEbHI5UUN3ME2yNk4xPDVizszN M2fqTHNCVkeHUh?=
D-502MG NUjYfpNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHJNpVTUUN3ME2yNk45OjZzIN88US=> NWPROoF2W0GQR1XS
IA-LM M2rtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nkbmlEPTB;MkOuNlQ6OyEQvF2= MoXFV2FPT0WU
SW1463 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJ|Lke5JO69VQ>? NIjFVZBUSU6JRWK=
JAR NVu1W3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJ2LkOyPVMh|ryP M1r2dnNCVkeHUh?=
HT NWr3T44xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTrZ5IzUUN3ME2yOE41PzV|IN88US=> MljMV2FPT0WU
LCLC-103H NHTweGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ2Lki0OFkh|ryP NUH0SI9sW0GQR1XS
SNU-449 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPDTWM2OD1{ND64O|QyKM7:TR?= NHT6W45USU6JRWK=
KE-37 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\HSmZKSzVyPUK1MlA6OjhizszN NIjWb2hUSU6JRWK=
NCI-H1623 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHIcmIzUUN3ME2yO{4yOzB|IN88US=> NFi1ZZVUSU6JRWK=
MOLT-13 NHvY[5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ5LkO1NVYh|ryP MUTTRW5ITVJ?
COLO-741 Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHoU4JKSzVyPUOxMlM{OzNizszN Ml7QV2FPT0WU
NB6 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7WTWM2OD1|Mj6yPFc3KM7:TR?= NHy3U4xUSU6JRWK=
MOLT-16 NHm1eJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HTfmlEPTB;M{OuNFA2PSEQvF2= MkjpV2FPT0WU
IST-MES1 NEfLWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e0[2lEPTB;M{SuNFU1OSEQvF2= MlHMV2FPT0WU
A4-Fuk NUTSUIs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorQTWM2OD1|NT6wOlYh|ryP NGn3NZFUSU6JRWK=
CAL-85-1 M4n4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjRTWM2OD1|NT6yPFE4KM7:TR?= MX\TRW5ITVJ?
CCRF-CEM MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDaPWFKSzVyPUO3MlE2OzZizszN MkfKV2FPT0WU
HAL-01 NUflSYZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTN6LkS4PFkh|ryP MUXTRW5ITVJ?
HEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDUOnVCUUN3ME20N{4{PDB7IN88US=> MV\TRW5ITVJ?
EW-1 M1PEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTR|LkS3Olgh|ryP NUGweVRMW0GQR1XS
MDA-MB-231 NGe3NmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTPRohrUUN3ME20OU4yOTl7IN88US=> MUHTRW5ITVJ?
ABC-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTR4Lki1N|gh|ryP MWrTRW5ITVJ?
NCI-H446 M1ftNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHpV2NUUUN3ME20PE42ODV6IN88US=> NFPEW4pUSU6JRWK=
MHH-PREB-1 M1jjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTJTWM2OD12OT62NFA4KM7:TR?= NXHmWY5pW0GQR1XS
DOHH-2 NIrvdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PmdGlEPTB;NEmuOlY2PiEQvF2= NHKzT2xUSU6JRWK=
GCT M3XpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDJNVhKSzVyPUS5MlY6PzZizszN NXO0[o86W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay:[1]
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:[1]
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water Insoluble
In vivo Add solvents individually and in order:
5%DMSO+corn oil
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy Tanespimycin (17-AAG) | Tanespimycin (17-AAG) supplier | purchase Tanespimycin (17-AAG) | Tanespimycin (17-AAG) cost | Tanespimycin (17-AAG) manufacturer | order Tanespimycin (17-AAG) | Tanespimycin (17-AAG) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID